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Background: Atrial fibrillation is one of the most common abnormal heart rhythms. Neutrophil-
lymphocyte ratio (NLR) has emerged as a potential marker for the level of inflammation in car-
diac disorders.
Hypothesis: NLR might be associated with thrombosis and bleeding risk scores and might pre-
dict cardioembolic risk in nonvalvular atrial fibrillation (NVAF) patients within the therapeutic
international normalized ratio (INR).
Methods: We enrolled 272 patients taking warfarin for NVAF and classified them into 2 groups:
Group A consisted of patients (n = 132) whose time in therapeutic range (TTR) was ≥65%, and
Group B comprised patients (n = 139) whose TTR was <65%.
Results: NLR values were higher in group B than in group A (P < 0.0001). Patients classified as
high risk according to CHA2DS2-VASc score had significantly higher NLR levels (P = 0.002)
than those classified as low and intermediate risk. Furthermore, NLR levels were significantly
correlated with CHA2DS2-VASc and HAS-BLED scores (P < 0.001 and P < 0.0001, respec-
tively). NLR predicted patients within therapeutic INR range (TTR ≥65%) with sensitivity of
81% and specificity of 71% in a receiver operator characteristic curve analysis, using a cutoff
value of 2.17. Area under the curve for NLR was 0.81 (P < 0.0001).
Conclusions: To our knowledge, this is the first study showing correlation of NLR with both
CHA2DS2-VASc and HAS-BLED risk scores. NLR might represent a useful marker to identify
patients with high risks of stroke and bleeding and may have predictive value in identifying
patients within the therapeutic INR range.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most frequently sustained arrhythmia in
clinical practice.1 AF is associated with significant morbidity and
mortality, and it is a major risk factor for thromboembolic events
and death from all causes.2 Numerous scoring systems have been
proposed to predict thromboembolism risk in AF patients. Among
these, the CHA2DS2-VASc score is currently the recommended clini-
cal risk-prediction tool to evaluate the thromboembolism risk in
patients with nonvalvular atrial fibrillation (NVAF).3 The HAS-BLED
score is the most widely preferred method for the prediction of
bleeding risk.4
Warfarin, a vitamin K antagonist, is prescribed to many patients
to combat the risk of thromboembolism. In such patients, routine
follow-up is required at regular intervals to achieve target interna-
tional normalized ratio (INR) values. However, achieving and main-
taining the target INR range remains a problem of warfarin treatment.
The risk of thromboembolism increases in patients with an INR value
below the target INR range, and the risk of bleeding increases in
those who exceed the target INR range. The most feasible method
for quantitative assessments of the therapeutic effectiveness of vita-
min K antagonists over time is measurement of the percentage of
time in therapeutic range (TTR). TTR has been shown to correlate
strongly with the clinical outcomes of hemorrhage or thrombosis
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and to be a reliable measure of the quality of anticoagulation
management.5
Current evidence reveales that the pathophysiology of AF is mul-
tifactorial. Recent studies showed that inflammation playes a key role
in the initiation, maintenance, and recurrence of AF.6,7 The
neutrophil-lymphocyte ratio (NLR) is a simple, inexpensive, and
widely available biomarker. It has been shown that NLR is also a
marker of inflammation.8 Thus, NLR might serve as an effective pre-
dictor of outcomes in AF.9
The primary aim of this study was to investigate the role of NLR
in predicting thrombosis or bleeding risk scores in patients with
NVAF. A secondary aim was to evaluate the predictive value of NLR
for cardioembolic risk in NVAF patients in the therapeutic INR range.
2 | METHODS
2.1 | Study population
This was a retrospective single-center study based on medical
records. In total, 271 NVAF patients admitted to our outpatient cardi-
ology clinic for routine INR examinations were enrolled in this study.
All the patients had taken warfarin for >3 months. Previous research
showed that the percentage of time that patients taking warfarin had
an INR of 2.0 to 3.0 within the target value (ie, TTR) was important
for the safety and effectiveness of warfarin anticoagulation and sug-
gested that a TTR of >65% indicated good control.5 Therefore, in the
present study, the patients were divided into 2 groups: those with a
TTR ≥65% and those with a TTR <65%.
All the patients were screened for the presence of cardiovascular
(CV) risk factors, such as hypertension, diabetes mellitus, stroke his-
tory, sex, age, and chronic renal failure. The inclusion criteria were
NVAF patients age > 18 years who presented to the cardiology out-
patient clinic and had used warfarin for >3 months. The exclusion cri-
teria included autoimmune disease, clinically significant valvular heart
disease, acute coronary syndrome, acute renal failure, acute heart
failure, acute stroke, cancer, ongoing infection, or systemic inflamma-
tory conditions. Patients with high C-reactive protein values (>3 mg/
L) were also excluded. The medical history and clinical features of the
patients were recorded. This study was approved by the local institu-
tional ethics committee.
2.2 | Measurement instruments and laboratory
parameters
The CHA2DS2-VASc
10 scoring system was used to stratify the risk of
long-term thromboembolic events related to AF, and the HAS-BLED
score4 was used to determine bleeding risk. The patients were also
classified into different risk groups according to the CHA2DS2-VASc
thromboembolic risk score and HAS-BLED bleeding risk score, as fol-
lows: a low-intermediate thromboembolic risk group (score 0 or 1),
high thromboembolic risk group (score ≥ 2), low-intermediate bleed-
ing risk group (score < 3), and high bleeding risk group (score ≥ 3).
Blood samples were collected from the antecubital vein using a 21-
gauge sterile syringe in the laboratory. Neutrophils and lymphocytes
were obtained from a complete blood count. The NLR was calculated
based on the ratio of absolute counts of neutrophils and
lymphocytes.
2.3 | Calculation of TTR
The INRs of patients were obtained from their outpatient clinic medi-
cal reports, where every patient had ≥3 INR measurements. TTR was
calculated according to F.R. Rosendaal's algorithm.11
2.4 | Statistical analysis
All statistical data were analyzed using SPSS version 15.0 for Win-
dows (SPSS Inc., Chicago, IL). Continuous data are expressed as mean
 SD, and the categorical data are expressed as percentages. Contin-
uous variables were tested for normal distribution by the
Kolmogorov–Smirnov test. Comparisons between groups were per-
formed using the χ2 or Fisher exact test for qualitative variables when
appropriate, the independent t test for normally distributed continu-
ous variables, and the Mann–Whitney U test for non–normally dis-
tributed continuous variables. The Pearson test was used in the
correlation analysis between parametric variables. To determine the
ideal cutoff value of the NLR, a receiver operating characteristic
(ROC) curve was used. A P value <0.05 was considered significant.
3 | RESULTS
The study population included 107 men and 164 women, with a
mean age of 70.25  9.35 years. Group A included 132 patients with
TTR ≥65%, and Group B comprised 139 patients with TTR <65%.
Baseline demographic, clinical, and laboratory characteristics of the
2 groups are presented in Table 1. There were no differences in base-
line clinical characteristics of the groups, such as age, sex, hyperten-
sion, diabetes mellitus, heart failure, vascular disease, and a previous
history of stroke (P > 0.05).
Each group was compared according to NLR values, CHA2DS2-
VASc scores, and HAS-BLED scores (Table 2). The NLR was signifi-
cantly higher in group B as compared with that in group A
(P < 0.0001). CHA2DS2-VASc and HAS-BLED scores were also higher
in group B than in Group A (P = 0.028 and P < 0.0001, respectively).
When the low-intermediate and high-risk CHA2DS2-VASc score
groups were compared with the NLRs of the groups, the NLR of the
high-risk group was significantly higher than that of the low-
intermediate risk group (2.64  1.26 vs 1.97  0.76; P = 0.002).
However, there was no significant difference between low-
intermediate and high HAS-BLED score groups (2.49  1.28 vs
2.78  1.15; P = 0.084). Furthermore the NLR showed a significant
correlation with CHA2DS2-VASc and HAS-BLED scores (P < 0.001,
r = 0.205; and P < 0.0001, r = 0.228, respectively).
The ROC analysis showed that NLR predicted TTR (≥65%) with
81% sensitivity and 71% specificity, using a cutoff value of 2.17
(ROC area: 0.812, 95% confidence interval: 0.76-0.86, P < 0.0001).
Using a cutoff value of 1.70, the sensitivity increased to 90%. The
ROC curve of the NLR is shown in the Figure 1.
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4 | DISCUSSION
The present study consisted of patients admitted to the cardiology
outpatient clinic who used warfarin and had a diagnosis of NVAF.
The results revealed a correlation between NLR and thromboembolic
and bleeding risk scores. The NLR was a predictive marker of patients
within the therapeutic INR range.
The NLR is a novel parameter, investigated in conditions with
inflammatory pathogenesis, and has been widely studied in CV dis-
eases.12 It was reported to be a strong predictor of adverse CV out-
come.13 Previous studies also demonstrated that NLR was associated
with inflammation and thrombogenicity.14,15 Furthermore, a high pre-
operative NLR was related to an increased incidence of AF in coro-
nary artery bypass grafting patients after surgery.16 In a study of a
patient population with diabetes, the NLR was significantly higher in
an AF group than an AF-free group, and it was an independent risk
factor for AF.17 A similar study found that NLR was higher in persis-
tent/permanent NVAF patients than in cases of paroxysmal AF.18
A previous study of AF patients detected a history of strokes,
transient ischemic attacks, or systemic thromboembolisms in 16% of
all patients, in addition to a history of bleeding in 14% of patients.19
In a study of patients with NVAF, a high NLR was an independent
risk factor for the presence of a left atrial thrombus on transesopha-
geal echocardiography.14 A large retrospective cohort showed that
each increase in NLR quartile was associated with a significant incre-
ment in the risk of strokes and that adding the NLR to the CHA2DS2-
VASc risk score improved the accuracy of stroke prediction.20 NLR
has been shown to increase the risk of thromboembolic stroke in
patients with NVAF.9 In the same study, the mean NLR of stroke
patients was significantly higher than that of nonstroke patients.
Akdag et al. revealed that the NLR was correlated with the
CHA2DS2-VASc score in patients with NVAF, which was an indepen-
dent predictor of a high CHA2DS2-VASc score.
21 In the present
study, the NLR was higher in the high CHA2DS2-VASc group, and the
NLR was correlated with the CHA2DS2-VASc score, in accordance
with the findings of a previous study. In addition, this study revealed
a significant correlation between NLR and HAS-BLED score. The
CHA2DS2-VASc score was higher in group B (TTR <65%). The results
of the present study indicate that the NLR might be a useful parame-
ter to detect the risk of thromboembolism and bleeding.
4.1 | Study limitations
The retrospective design is the main limitation of this study. More-
over, this study was based on single-center experiments. Another lim-
itation of this study was the relatively small sample size.
5 | CONCLUSION
Risk stratification is essential to determine thromboembolic and
bleeding risk in patients with NVAF. The NLR, which can be mea-
sured by an inexpensive and simple method, might represent a useful
marker to identify patients with high thromboembolic and bleeding
risk in patients with NVAF. To our knowledge, this is the first study
to demonstrate a correlation of NLR with the CHA2DS2-VASc and
HAS-BLED risk scores. The NLR was strongly associated with both
scoring systems. Therefore, we suggest that NLR can be used as a
TABLE 1 Baseline demographic, clinical, and laboratory
characteristics of groups A and B
Group A, TTR
≥65%, n = 132
Group B, TTR
<65%, n = 139
P
Value
Age, y 69.11  8.87 70.97  9.26 0.092
Female sex 76 (58) 82 (59) 0.813
Cr, mg/dL 1.03  0.19 1.05  0.32 0.627
HTN 83 (63) 87 (63) 0.941
DM 40 (30) 40 (29) 0.783
Hyperlipidemia 33 (25) 26 (19) 0.209
Stroke 12 (9) 20 (15) 0.130
COPD 23 (17) 35 (25) 0.120
Abbreviations: COPD, chronic obstructive pulmonary disease; Cr, creati-
nine; DM, diabetes mellitus; HTN, hypertension; SD, standard deviation;
TTR, time in therapeutic range. Data are presented as n (%) or
mean  SD.
FIGURE 1 The ROC curve analysis of NLR for predicting the TTR
≥65%. Abbreviations: NLR, neutrophil-lymphocyte ratio; ROC,
receiver operating characteristic; TTR, time in therapeutic range
TABLE 2 Comparison of groups with respect to NLR, CHA2DS2-
VASc, and HAS-BLED scores with independent t test
Score Group A Group B P Value
NLR 1.94  0.71 3.21  1.58 <0.0001
CHA2DS2-VASc 3.12  1.32 3.48  1.33 <0.05
HAS-BLED 1.80  0.74 2.58  0.98 <0.0001
Abbreviations: CHA2DS2-VASc, congestive HF, HTN, age ≥ 75 y, DM,
stroke/TIA, vascular disease, age 65–74 y, sex category (female); DM, dia-
betes mellitus; HAS-BLED, abnormal renal and liver function, stroke,
bleeding history or predisposition, labile INR, elderly age > 65 years; HF,
heart failure; HTN, hypertension; INR, international normalized ratio; NLR,
neutrophil-lymphocyte ratio; SD, standard deviation; TIA, transient ische-
mic attack. Data are presented as mean  SD.
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simple and inexpensive adjunct to CHA2DS2-VASc and HAS-BLED
scores to predict thromboembolic and bleeding risk. The NLR may
also be helpful to identify patients within the therapeutic INR range.
Further studies with larger sample sizes are needed to elucidate the
role of the NLR as an additional risk-stratification tool in patients
with NVAF.
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